Verqalif 2,5 mg, 5 mg & 10 mg Tablet
PDF Leaflet Revision Date: 15 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of symptomatic chronic heart failure with reduced ejection fraction.
Dosage (summary)
Start at 2.5 mg once daily, titrate to 10 mg once daily as tolerated.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Concomitant use with other sGC stimulators
- PDE5 inhibitors
Contraindications
- Hypersensitivity to vericiguat or excipients
- Severe renal impairment (eGFR <15 mL/min/1.73 mu00b2)
- Severe hepatic impairment (Child-Pugh class C)
Common side effects
- Hypotension
- Dizziness
- Nausea
- Headache
Counselling Points
- Take with food
- Monitor blood pressure regularly
- Report any symptoms of hypotension
Serious warnings
- Risk of symptomatic hypotension
- Not studied in patients with SBP <100 mmHg
Important Disclaimer
The Verqalif 2,5 mg, 5 mg & 10 mg Tablet professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
